Skip to content

Clinical efficacy and mechanism of acupuncture in the treatment of osteoarthralgia caused by aromatase inhibitors in breast cancer

Clinical efficacy and mechanism of acupuncture in the treatment of osteoarthralgia caused by aromatase inhibitors in breast cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006739
Enrollment
Unknown
Registered
2022-11-01
Start date
2022-11-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthralgia due to aromatase inhibitors in breast cancer

Interventions

sham acupuncture group:sham acupuncture
Acupuncture group:acupuncture

Sponsors

Beijing Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Patients with histopathological confirmed (stage I-III) primary breast cancer, immunohistochemistry showing estrogen receptor and/or progesterone receptor positive; (2) be between 35 and 75 years old; (3) No metastasis to other locations occurred after breast cancer surgery, and systemic symptoms have recovered from the side effects of surgery and the reaction of radiotherapy and chemotherapy; (4) Have been taking aromatase inhibitors for more than 30 days and plan to continue to use them for at least 1 year; (5) Single or multiple bone and joint pain symptoms, and the most severe pain item (BPI-WP) score in the Abbreviated Pain Scale (BPI) is greater than 3 points; (6) Those who voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Currently receiving other topical analgesics; (2) Those suffering from autoimmune diseases and other non-AIs-induced joint pain; (3) Combining severe primary diseases such as liver, kidney, hematopoietic system, opioid Analgesics, sedative-hypnotics and alcohol abuse history; (4) patients with severe acupuncture intolerance; (5) pregnant and lactating women; (6) patients diagnosed with metastatic breast cancer; (7) ) received acupuncture and closed treatment in the last 3 months; (8) patients who were unable to participate in the follow-up and were unable to participate in the six-month follow-up; (9) are currently participating in other clinical trials related to AIA.

Design outcomes

Primary

MeasureTime frame
Change in scores for the Brief Pain Scale (BPI) Most Severe Pain Item (BPI-WP) after 6 weeks of treatment; Mechanistic inflammatory indicators: changes in the content of pro-inflammatory cytokines (IL-1ß, IL-6, TNF-a) after 6 weeks of treatment.;

Secondary

MeasureTime frame
Pain indicators; Quality of life indicators;

Countries

China

Contacts

Public ContactLi Zhonglong
lizhonglongbaby@163.com13681051073

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026